Join us on September 11 to discover how advances in antibody engineering and T-cell therapy are opening new possibilities for treating some of the most challenging cancers. In this seminar featuring Mitchell Ho, PhD, Senior Investigator and Deputy Chief of Laboratory Biology for the National Cancer Institute, you will gain insight into emerging approaches to therapeutic discovery, including the targeting of glypicans in cancer, novel antibody platforms, and the development of CAR T-cell therapies now advancing into clinical trials for liver cancer, pediatric cancers, mesothelioma, and other malignancies.
Ho leads an internationally recognized research program at the NCI focused on translating discoveries in cancer biology into antibody- and T-cell-based immunotherapies. His pioneering work spans glypican biology, mammalian cell display technology, and single-domain antibody platforms, offering attendees a compelling look at how innovative laboratory science can lead to new therapeutic strategies for patients.